What is the diagnosis and management for a patient with a negative indirect Coombs (Indirect Antiglobulin Test) test and a positive direct Coombs (Direct Antiglobulin Test) test, indicating immune-mediated hemolysis?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 30, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Diagnosis: Autoimmune Hemolytic Anemia (AIHA)

A positive direct Coombs test with a negative indirect Coombs test indicates immune-mediated hemolysis occurring on the patient's own red blood cells, confirming the diagnosis of autoimmune hemolytic anemia (AIHA). 1

Understanding the Coombs Test Pattern

  • Direct Coombs (DAT) positive means antibodies or complement are already bound to the patient's red blood cells, indicating active immune destruction 2, 1
  • Indirect Coombs negative means there are no free-floating antibodies in the serum, distinguishing this from alloimmunization scenarios 3, 4
  • This pattern is pathognomonic for AIHA, where antibodies are coating the patient's own RBCs causing hemolysis 1

Immediate Diagnostic Workup

Complete the hemolysis panel immediately:

  • Lactate dehydrogenase (LDH) - expect elevation 2
  • Haptoglobin - expect decreased or undetectable (<25 mg/dL) 2
  • Indirect bilirubin - expect elevation (>1.2 mg/dL) 2
  • Reticulocyte count - assess bone marrow response 2, 1
  • Peripheral blood smear - look for spherocytes 2

Assess severity and complications:

  • Complete blood count with differential - determine anemia severity 2
  • Platelet count - rule out Evans syndrome or thrombotic microangiopathy 2
  • Creatinine and urinalysis - exclude concurrent TMA 2

Identify underlying cause:

  • Autoimmune workup: ANA, rheumatoid factor, HLA-B27 1
  • Screen for infections: viral/bacterial causes 1
  • Review medications - consider drug-induced hemolytic anemia 3
  • Consider lymphoproliferative disorders or immune checkpoint inhibitor exposure 3, 1

Initial Management Algorithm

For severe anemia (Hb <8 g/dL):

  • Initiate prednisone 1-2 mg/kg/day orally immediately 1
  • Hospitalize for close monitoring 1
  • Transfuse RBCs only if Hb <7-8 g/dL or symptomatic 2, 1
  • Consult hematology and rheumatology urgently 1
  • Supplement with folic acid 1 mg daily 1

For moderate anemia (Hb 8-10 g/dL):

  • Start prednisone 1 mg/kg/day orally 1
  • Monitor hemoglobin weekly 1
  • Consider rheumatology consultation 1
  • Add folic acid 1 mg daily 1

For mild anemia (Hb ≥10 g/dL):

  • Consider lower dose prednisone 0.5-1 mg/kg/day 1
  • Monitor with weekly CBC 1
  • Complete autoimmune workup 1

Response Assessment and Escalation

Evaluate treatment response after 1-2 weeks:

  • Monitor hemoglobin and reticulocyte response weekly until stabilized 1
  • If no improvement after 3 weeks of corticosteroids, escalate to second-line therapy 1

Second-line options for steroid-refractory disease:

  • Rituximab 1
  • Intravenous immunoglobulin (IVIG) 3, 1
  • Immunosuppressive agents (mycophenolate mofetate, cyclosporine) 3
  • Splenectomy 1

Critical Management Pitfalls

Do not delay treatment while awaiting complete workup - begin corticosteroids immediately once AIHA is confirmed 1

Do not transfuse unnecessarily - RBC transfusion should only be given for Hb <7-8 g/dL or symptomatic anemia, as transfusion can worsen hemolysis 2, 1

Do not miss thrombotic microangiopathy - if thrombocytopenia is present alongside hemolysis, immediately check ADAMTS13 activity and evaluate for TMA, as this requires different management 2

Do not taper corticosteroids prematurely - maintain full dose for 4-6 weeks before initiating slow taper 1

Do not overlook drug-induced causes - review all medications, particularly immune checkpoint inhibitors, which may require permanent discontinuation 3

Do not ignore underlying malignancy or autoimmune disease - complete the autoimmune and infectious workup even as treatment begins 1

Special Considerations

In patients receiving immune checkpoint inhibitors: This pattern may represent an immune-related adverse event requiring permanent discontinuation of immunotherapy and high-dose corticosteroids 3

Coombs-negative AIHA exists: Approximately 40% of immune checkpoint inhibitor-associated AIHA and 2-10% of warm AIHA cases may have negative DAT despite true immune hemolysis 3, 5, 6, 7. However, your scenario describes a positive DAT, confirming the diagnosis.

References

Guideline

Management of Autoimmune Hemolytic Anemia

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Laboratory Evaluation of Hemolysis

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Workup Following a Positive Indirect Coombs Test

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

[Coombs negative autoimmune hemolytic anemia in a patient with myelodysplastic syndrome].

[Rinsho ketsueki] The Japanese journal of clinical hematology, 1991

Research

[Application of the gel test using and anti-IgA antiglobulin for the immunologic diagnosis of autoimmune hemolytic anemia with a negative direct Coombs test].

Transfusion clinique et biologique : journal de la Societe francaise de transfusion sanguine, 1999

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.